Condition
Genitourinary Cancer
ClinicalTrials.gov condition label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 24 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
24 shownStudy of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)NCT07524114 · 2026-03-31
RECRUITINGRiluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot TrialNCT07447050 · 2025-12-23
RECRUITINGRepurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot TrialNCT06580002 · 2024-12-02
RECRUITINGHigh-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection MarginsNCT06835426 · 2023-08-06
RECRUITINGA Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract MalignanciesNCT04923178 · 2022-10-24
RECRUITINGInvestigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible SensitivityNCT04273061 · 2020-06-17
RECRUITINGCirculating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid TumorsNCT04354064 · 2019-05-29
RECRUITINGOntario-wide Cancer TArgeted Nucleic Acid EvaluationNCT02906943 · 2016-08-01
RECRUITINGGenomic Investigation of Unusual RespondersNCT03740503 · 2013-11-01
RECRUITINGAutologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerNCT06253520 · 2024-05-16
ACTIVE_NOT_RECRUITINGMind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive InterventionNCT06168825 · 2024-01-17
COMPLETEDAdapting the Tumor Board Model for Mental Illness and CancerNCT05837598 · 2023-05-31
UNKNOWNPathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)NCT05629065 · 2022-11-28
ACTIVE_NOT_RECRUITINGImpact of COVID-19 on GU DiseaseNCT04761107 · 2021-02-18
ACTIVE_NOT_RECRUITINGBintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary MalignanciesNCT04235777 · 2020-07-13
ACTIVE_NOT_RECRUITINGNivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsNCT03333616 · 2017-12-28
ACTIVE_NOT_RECRUITINGPROMOTE: Identifying Predictive Markers of Response for Genitourinary CancerNCT02735252 · 2016-05-25
ACTIVE_NOT_RECRUITINGFeasibility of Activity Monitoring in Patients With Cancer: Physical Activity Monitoring in Cancer Patients (PAMCaP)NCT02583815 · 2015-08-01
COMPLETEDA Feasibility Trial of Geriatric Assessment and Management for Older Cancer PatientsNCT02222259 · 2014-09-01
COMPLETEDPersonal Web Page In Clinical Trial Participant EducationNCT03887091 · 2014-07-21
COMPLETEDInflammatory Response and Tissue Fibrosis/ Lymphatico-venous BypassNCT01433302 · 2012-03-01
COMPLETEDIntegrated Molecular Profiling in Advanced Cancers TrialNCT01505400 · 2012-02-01
ACTIVE_NOT_RECRUITINGDoxorubicin With or Without Sildenafil, With Analysis of Cardiac MarkersNCT01375699 · 2011-08-11
COMPLETEDA Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle ContrastNCT00147238 · 2005-07-01
TERMINATEDCommon interventions
RiluzoleDRUG2AldesleukinDRUG1AtezolizumabDRUG1Clinician Nudge EmailOTHER1CyclophosphamideDRUG1DoxorubicinDRUG1Ferumoxtran-10 (USPIO)DRUG1FludarabineDRUG1GA and Integrated Care PlanPROCEDURE1GRT-C903/GRT-R904BIOLOGICAL1Imaging resected specimen using the high-resolution PET-CT specimen imagerDIAGNOSTIC_TEST1IpilimumabDRUG1KRAS TCR-Transduced PBLBIOLOGICAL1M7824DRUG1Mind Over Matter (MOM)OTHER1MR lymphangiographyPROCEDURE1NivolumabDRUG1Patient Nudge Letter and Share questionaireOTHER1PDS01ADCDRUG1PlaceboDRUG1PlaceboOTHER1PostwireOTHER1Punch BiopsyPROCEDURE1SildenafilDRUG1Single intravenous injection of the radiotracerOTHER1
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
University Health Network, Toronto
4
Dana-Farber Cancer Institute
3
National Cancer Institute (NCI)
3
M.D. Anderson Cancer Center
2
University of California, Irvine
2
Algemeen Ziekenhuis Maria Middelares
1
British Columbia Cancer Agency
1
Icahn School of Medicine at Mount Sinai
1
Inova Health Care Services
1
Massachusetts General Hospital
1
University of California, San Francisco
1
University of Texas Southwestern Medical Center
1
University of Toronto
1
Virginia Commonwealth University
1
Washington University School of Medicine
1
Trial status mix
RECRUITING9
ACTIVE_NOT_RECRUITING7
COMPLETED6
TERMINATED1
UNKNOWN1
Phase mix
NA7
PHASE24
PHASE13
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.